# Naoya Uchida

List of Publications by Year
in descending order



| 73 | 1,813 | 279487 23 | 301761 39 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 75 | 75 | 75 | 2284 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Hematopoietic Stem Cell Gene-Addition/Editing Therapy in Sickle Cell Disease. Cells, 2022, 11, 1843. | 1.8 | 12 |
| 2 | A macaque clonal hematopoiesis model demonstrates expansion of TET2-disrupted clones and utility forÂtesting interventions. Blood, 2022, 140, 1774-1789. | 0.6 | 13 |
| 3 | Optimizing haematopoietic stem and progenitor cell apheresis collection from plerixaforâ€mobilized patients with sickle cell disease. British Journal of Haematology, 2022, 198, 740-744. | 1.2 | 8 |
| 4 | Commentary on Winzeler et al â€˜Low arginine vasopressin levels in patients with diabetes insipidus are not associated with anaemiaâ€™. Clinical Endocrinology, 2021, 94, 888-890. | 1.2 | 1 |
| 5 | Hematopoietic Stem Cell-Targeted Gene-Addition and Gene-Editing Strategies for Î²-hemoglobinopathies. Cell Stem Cell, 2021, 28, 191-208. | 5.2 | 17 |
| 6 | Gene replacement of Î±-globin with Î²-globin restores hemoglobin balance in Î²-thalassemia-derived hematopoietic stem and progenitor cells. Nature Medicine, 2021, 27, 677-687. | 15.2 | 51 |
| 7 | Sustained fetal hemoglobin induction in vivo is achieved by BCL11A interference and coexpressed truncated erythropoietin receptor. Science Translational Medicine, 2021, 13, . | 5.8 | 6 |
| 8 | Preclinical evaluation for engraftment of CD34+ cells gene-edited at the sickle cell disease locus in xenograft mouse and non-human primate models. Cell Reports Medicine, 2021, 2, 100247. | 3.3 | 15 |
| 9 | Disease severity impacts plerixafor-mobilized stem cell collection in patients with sickle cell disease. Blood Advances, 2021, 5, 2403-2411. | 2.5 | 24 |
| 10 | Cas9 protein delivery non-integrating lentiviral vectors for gene correction in sickle cell disease. Molecular Therapy - Methods and Clinical Development, 2021, 21, 121-132. | 1.8 | 25 |
| 11 | CD117 Antibody Drug Conjugate-Based Conditioning Allows for Efficient Engraftment of Gene-Modified CD34+ Cells in a Rhesus Gene Therapy Model. Blood, 2021, 138, 560-560. | 0.6 | 3 |
| 12 | Immunoresponse to Gene-Modified Hematopoietic Stem Cells. Molecular Therapy - Methods and Clinical Development, 2020, 16, 42-49. | 1.8 | 16 |
| 13 | Definitive hematopoietic stem/progenitor cells from human embryonic stem cells through serum/feeder-free organoid-induced differentiation. Stem Cell Research and Therapy, 2020, 11, 493. | 2.4 | 13 |
| 14 | Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease. Blood Advances, 2020, 4, 2058-2063. | 2.5 | 93 |
| 15 | Î²T87Q-Globin Gene Therapy Reduces Sickle Hemoglobin Production, Allowing for ExÂVivo Anti-sickling Activity in Human Erythroid Cells. Molecular Therapy - Methods and Clinical Development, 2020, 17, 912-921. | 1.8 | 13 |
| 16 | Safe and efficient peripheral blood stem cell collection in patients with sickle cell disease using plerixafor. Haematologica, 2020, 105, e497. | 1.7 | 29 |
| 17 | Biallelic correction of sickle cell diseaseâ€derived induced pluripotent stem cells (iPSCs) confirmed at the protein level through serumâ€free iPSâ€sac/erythroid differentiation. Stem Cells Translational Medicine, 2020, 9, 590-602. | 1.6 | 17 |
| 18 | BCL11A enhancerâ€“edited hematopoietic stem cells persist in rhesus monkeys without toxicity. Journal of Clinical Investigation, 2020, 130, 6677-6687. | 3.9 | 54 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Intrabone transplantation of CD34+ cells with optimized delivery does not enhance engraftment in a rhesus macaque model. Blood Advances, 2020, 4, 6148-6156. | 2.5 | 5 |
| 20 | Busulfan Combined with Immunosuppression Allows Efficient Engraftment of Gene-Modified Cells in a Rhesus Macaque Model. Molecular Therapy, 2019, 27, 1586-1596. | 3.7 | 28 |
| 21 | Robust generation of erythroid and multilineage hematopoietic progenitors from human iPSCs using a scalable monolayer culture system. Stem Cell Research, 2019, 41, 101600. | 0.3 | 23 |
| 22 | Development of a forward-oriented therapeutic lentiviral vector for hemoglobin disorders. Nature Communications, 2019, 10, 4479. | 5.8 | 21 |
| 23 | CRISPR/Cas9 for Sickle Cell Disease: Applications, Future Possibilities, and Challenges. Advances in Experimental Medicine and Biology, 2019, 1144, 37-52. | 0.8 | 37 |
| 24 | Fetal hemoglobin and F-cell variance in mobilized CD34+ cell-transplanted rhesus monkeys. Experimental Hematology, 2019, 75, 21-25.e1. | 0.2 | 3 |
| 25 | Aberrant Clonal Hematopoiesis following Lentiviral Vector Transduction of HSPCs in a Rhesus Macaque. Molecular Therapy, 2019, 27, 1074-1086. | 3.7 | 34 |
| 26 | High-Efficiency Lentiviral Transduction of Human CD34+ Cells in High-Density Culture with Poloxamer and Prostaglandin E2. Molecular Therapy - Methods and Clinical Development, 2019, 13, 187-196. | 1.8 | 31 |
| 27 | Bone marrow characterization in sickle cell disease: inflammation and stress erythropoiesis lead to suboptimal CD34 recovery. British Journal of Haematology, 2019, 186, 286-299. | 1.2 | 49 |
| 28 | Genome editing of HBG1 and HBG2 to induce fetal hemoglobin. Blood Advances, 2019, 3, 3379-3392. | 2.5 | 121 |
| 29 | Low-Dose Busulfan Reduces Human CD34+ Cell Doses Required for Engraftment in c-kit Mutant Immunodeficient Mice. Molecular Therapy - Methods and Clinical Development, 2019, 15, 430-437. | 1.8 | 21 |
| 30 | Preclinical Evaluation for Engraftment of Gene-Edited CD34+ Cells with a Sickle Cell Disease Mutation in a Rhesus Transplantation Model. Blood, 2019, 134, 609-609. | 0.6 | 2 |
| 31 | Truncated Erythropoietin Receptors Confer an In Vivo Selective Advantage in Gene-Modified Erythroid Cells Expressing Fetal Hemoglobin Due to BCL11A Interference. Blood, 2019, 134, 2063-2063. | 0.6 | 2 |
| 32 | A Single Dose of CD117 Antibody Drug Conjugate Enables Autologous Gene-Modified Hematopoietic Stem Cell Transplant (Gene Therapy) in Nonhuman Primates. Blood, 2019, 134, 610-610. | 0.6 | 14 |
| 33 | Durable and Robust Fetal Globin Induction without Anemia in Rhesus Monkeys Following Autologous Hematopoietic Stem Cell Transplant with BCL11A Erythroid Enhancer Editing. Blood, 2019, 134, 4632-4632. | 0.6 | 6 |
| 34 | High-level embryonic globin production with efficient erythroid differentiation from a K562 erythroleukemia cell line. Experimental Hematology, 2018, 62, 7-16.e1. | 0.2 | 10 |
| 35 | Robust erythroid differentiation system for rhesus hematopoietic progenitor cells allowing preclinical screening of genetic treatment strategies for the hemoglobinopathies. Cytotherapy, 2018, 20, 1278-1287. | 0.3 | 6 |
| 36 | Serum-free Erythroid Differentiation for Efficient Genetic Modification and High-Level Adult Hemoglobin Production. Molecular Therapy - Methods and Clinical Development, 2018, 9, 247-256. | 1.8 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Gene therapy for sickle cell disease: An update. Cytotherapy, 2018, 20, 899-910. | 0.3 | 84 |
| 38 | Bone Marrow as a Hematopoietic Stem Cell Source for Gene Therapy in Sickle Cell Disease: Evidence from Rhesus and SCD Patients. Human Gene Therapy Clinical Development, 2017, 28, 136-144. | 3.2 | 23 |
| 39 | RNA Trans-Splicing Targeting Endogenous Î²-Globin Pre-Messenger RNA in Human Erythroid Cells. Human Gene Therapy Methods, 2017, 28, 91-99. | 2.1 | 3 |
| 40 | Vasopressin stimulates the proliferation and differentiation of red blood cell precursors and improves recovery from anemia. Science Translational Medicine, 2017, 9, . | 5.8 | 26 |
| 41 | Efficient Generation of Î²-Globin-Expressing Erythroid Cells Using Stromal Cell-Derived Induced Pluripotent Stem Cells from Patients with Sickle Cell Disease. Stem Cells, 2017, 35, 586-596. | 1.4 | 39 |
| 42 | Bone Marrow Characterization in Sickle Cell Disease: Inflammation and Stress Erythropoiesis Lead to Suboptimal CD34 Recovery Compared to Normal Volunteer Bone Marrow. Blood, 2017, 130, 966-966. | 0.6 | 4 |
| 43 | Total body irradiation must be delivered at high dose for efficient engraftment and tolerance in a rhesus stem cell gene therapy model. Molecular Therapy - Methods and Clinical Development, 2016, 3, 16059. | 1.8 | 10 |
| 44 | Î²-Globin-Expressing Definitive Erythroid Progenitor Cells Generated from Embryonic and Induced Pluripotent Stem Cell-Derived Sacs. Stem Cells, 2016, 34, 1541-1552. | 1.4 | 48 |
| 45 | SENP1, but not fetal hemoglobin, differentiates Andean highlanders with chronic mountain sickness from healthy individuals among Andean highlanders. Experimental Hematology, 2016, 44, 483-490.e2. | 0.2 | 13 |
| 46 | Kinetics of lentiviral vector transduction in human CD34+ cells. Experimental Hematology, 2016, 44, 106-115. | 0.2 | 7 |
| 47 | Development of a New Generation, Forward-Oriented Therapeutic Vector for Hemoglobin Disorders. Blood, 2016, 128, 1172-1172. | 0.6 | 2 |
| 48 | Discordance in lymphoid tissue recovery following stem cell transplantation in rhesus macaques: an in vivo imaging study. Blood, 2015, 126, 2632-2641. | 0.6 | 15 |
| 49 | More Efficient Generation of Î²-Globin-Expressing Erythroid Cells Using Stromal Cell-Derived Induced Pluripotent Stem Cells. Blood, 2015, 126, 1150-1150. | 0.6 | 0 |
| 50 | Decitabine Suspends Human CD34+ Cell Differentiation and Proliferation during Lentiviral Transduction. PLoS ONE, 2014, 9, e104022. | 1.1 | 4 |
| 51 | TRIM5Î± Variations Influence Transduction Efficiency With Lentiviral Vectors in Both Human and Rhesus CD34 + Cells In Vitro and In Vivo. Molecular Therapy, 2014, 22, 348-358. | 3.7 | 26 |
| 52 | No Impact of Lentiviral Transduction on Hematopoietic Stem/Progenitor Cell Telomere Length or Gene Expression in the Rhesus Macaque Model. Molecular Therapy, 2014, 22, 52-58. | 3.7 | 4 |
| 53 | Path to the Clinic: Assessment of iPSC-Based Cell Therapies InÂVivo in a Nonhuman Primate Model. Cell Reports, 2014, 7, 1298-1309. | 2.9 | 84 |
| 54 | Efficient transduction of human hematopoietic repopulating cells with a chimeric HIV1-based vector including SIV capsid. Experimental Hematology, 2013, 41, 779-788.e1. | 0.2 | 14 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | The Chicken Hypersensitivity Site 4 Core Insulator Blocks Promoter Interference in Lentiviral Vectors. Human Gene Therapy Methods, 2013, 24, 117-124. | 2.1 | 17 |
| 56 | Integration-specific In Vitro Evaluation of Lentivirally Transduced Rhesus CD34+ Cells Correlates With In Vivo Vector Copy Number. Molecular Therapy - Nucleic Acids, 2013, 2, e122. | 2.3 | 20 |
| 57 | MASL1 induces erythroid differentiation in human erythropoietin-dependent CD34+ cells through the Raf/MEK/ERK pathway. Blood, 2013, 121, 3216-3227. | 0.6 | 27 |
| 58 | Peripheral Blood As a Source Of Cells For Regenerative Medicine Applications In Sickle Cell Disease. Blood, 2013, 122, 2209-2209. | 0.6 | 0 |
| 59 | Generation Of Mature Erythroid Cells From Human Embryonic Stem Cell Derived Sacs and Optimization Of Erythroid Cell Generation. Blood, 2013, 122, 2425-2425. | 0.6 | 4 |
| 60 | Discordance Between Peripheral Blood and Tissue CD4+ Lymphocyte Reconstitution In Rhesus Monkeys Following Autologous Hematopoietic CD34+ Cell Transplantation: An In Vivo imaging Study. Blood, 2013, 122, 2019-2019. | 0.6 | 2 |
| 61 | CD34+CXCR4(CD184)+ Cells Differentiate Into Myeloid Dendritic Cell Progenitors. Blood, 2013, 122, 4835-4835. | 0.6 | 0 |
| 62 | High-efficiency Transduction of Rhesus Hematopoietic Repopulating Cells by a Modified HIV1-based Lentiviral Vector. Molecular Therapy, 2012, 20, 1882-1892. | 3.7 | 33 |
| 63 | Prostaglandin E2 Enhances Human Cord Blood Stem Cell Xenotransplants and Shows Long-Term Safety in Preclinical Nonhuman Primate Transplant Models. Cell Stem Cell, 2011, 8, 445-458. | 5.2 | 250 |
| 64 | Accelerated lymphocyte reconstitution and long-term recovery afterÂtransplantation of lentiviral-transduced rhesus CD34+ cells mobilizedÂbyÂG-CSF and plerixafor. Experimental Hematology, 2011, 39, 795-805. | 0.2 | 34 |
| 65 | Chicken HS4 Insulators Have Minimal Barrier Function Among Progeny of Human Hematopoietic Cells Transduced With an HIV1-based Lentiviral Vector. Molecular Therapy, 2011, 19, 133-139. | 3.7 | 36 |
| 66 | Determining Limitations in Human CD34+ Cell Transduction with An HIV1-Based Lentiviral Vector,. Blood, 2011, 118, 4171-4171. | 0.6 | 3 |
| 67 | The Assessment of Human Erythroid Output in NOD/SCID Mice Reconstituted with Human Hematopoietic Stem Cells. Cell Transplantation, 2010, 19, 1465-1473. | 1.2 | 13 |
| 68 | Development of a Human Immunodeficiency Virus Type 1-Based Lentiviral Vector That Allows Efficient Transduction of both Human and Rhesus Blood Cells. Journal of Virology, 2009, 83, 9854-9862. | 1.5 | 53 |
| 69 | Busulfan Produces Efficient Human Cell Engraftment in NOD/LtSz-Scid IL2RÎ³ Null Mice. Stem Cells, 2009, 27, 175-182. | 1.4 | 60 |
| 70 | Leukemogenesis of b2a2-type p210 BCR/ABL in a Bone Marrow Transplantation Mouse Model Using a Lentiviral Vector. Journal of Nippon Medical School, 2009, 76, 134-147. | 0.3 | 19 |
| 71 | MLL-AF4 and FLT3 Activation Synergize To Induce Multi Step Leukemogenesis.. Blood, 2006, 108, 4321-4321. | 0.6 | 0 |
| 72 | Leukemogenesis of the b2a2 Type p210 BCR/ABL in a Bone Marrow Transplantation Mouse Model Using a Lentivirus Vector.. Blood, 2005, 106, 2875-2875. | 0.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Hematopoietic Differentiation of ES Cells from P230 Bcr/Abl Transgenic Mouse.. Blood, 2005, 106, 4331-4331. | 0.6 | 0 |